We leverage our passion, expertise, deep experience and network to help advance new technologies and build market leading companies. Delphi has helped several drugs achieve market approval. Our firm has enabled dozens of companies to expand therapeutic access for patients who need less invasive procedures.
Clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease, Congenital Adrenal Hyperplasia and autoimmune and inflammatory diseases.
Discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
Clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Development-stage biotechnology company dedicated to improving cancer treatment by discovering and developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells". They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
Focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Focused on the development and commercialization of the first fully implantable, long term continuous glucose monitoring system.
Novel technology in the development of a medical device for insulin administration.
Early phase development of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.
Instrumentation using focused acoustic energy to accurately dispense very small quantities of high-value fluids for pharmaceutical research.
Medical device technology for the in-office treatment of excessive menstrual bleeding.
Developing sustained release non-invasive drug delivery designed to lower intraocular pressure.
Contact lenses that combine the superior vision of a gas permeable lens with the comfort and ease of wear of a soft contact lens.
Deepa is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities.
She currently serves on the boards of Alder Biopharmaceuticals (Nasdaq:ALDR), Calithera Biosciences (Nasdaq: CALA), ForSight:Vision5, Karyopharm Therapeutics (Nasdaq:KPTI) and Oncomed Pharmaceuticals (Nasdaq:OMED).
Deepa previously served on the boards of Salmedix (acquired by Cephalon), Ilypsa (acquired by Amgen), Proteolix (acquired by Amgen), PTC Therapeutics (Nasdaq:PTCT) and Relypsa(Nasdaq:RYLP). She also led the investments in Cardeas Pharma, KAI Pharmaceuticals (acquired by Amgen), and a PIPE investment in Seattle Genetics (Nasdaq:SGEN).
Deepa joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice which focuses on drug discovery and development platform technologies that have resulted in multiple novel drugs, including six that are commercially marketed.
Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies that raised over $9 billion. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997.
She serves as Vice-Chair of the San Francisco Conservatory of Music’s Board of Trustees.
Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.
Doug joined Delphi Ventures as an Associate in 1998 and became a Partner in 2000. His primary investment focus at Delphi is on medical devices and diagnostics.
Doug currently serves on the boards of EBR Systems, Ivantis, Senseonics Holdings, and Tandem Diabetes Care. He previously served on the boards of Evalve (acquired by Abbott) and TriVascular (acquired by Endologix).
Prior to joining Delphi, Doug was an Associate with Alex. Brown's Healthcare Investment Banking Group in San Francisco. While at Alex. Brown Doug assisted in the execution of over a dozen financing and merger transactions involving both Fortune 500 and venture-backed medical technology companies, including a number of Delphi portfolio companies.
Previously, Doug was with Putnam Associates, a consulting firm focused on the biopharmaceutical industry, where his primary role was to develop and implement a strategy for the launch of a leading biotech drug.
As Chief Financial Officer, Matt has primary responsibility for Delphi's accounting and reporting. He also leads the firm's administrative and operational efforts including investor relations, human resources, information technology, legal affairs and portfolio company assistance.
Prior to joining Delphi Ventures in 2000, Matt spent three years as Controller at Bluecurve, Inc., an enterprise performance management software startup. He held various reporting and operational duties until the company's acquisition by Red Hat, Inc. (NYSE: RHT).
Prior to Bluecurve, he spent six years in public accounting with former Arthur Andersen managers Schorno, Murray & Co. providing audit, tax and business advisory services to private companies, real estate investment partnerships, and not-for-profit organizations.
Matt is a Certified Public Accountant and is a member of the California State Board of Accountants. He is a member of a NVCA CFO Task Force and has served on the West Coast Chapter Board of Directors of the Private Equity CFO Association (PECFOA).
Jim founded Delphi Ventures in 1988. His focus is on medical devices and biotechnology.
Jim began investing in medical companies in 1981 after co-founding Technology Venture Investors, a private venture capital partnership. Since 1984, he has focused exclusively on healthcare investments.
From 1976 to 1980, Jim was with Shugart Associates, a venture-backed disk drive company. As President and CEO, he led Shugart to increasing profitability, with annual revenues growing from $13 million to $200 million. Shugart was acquired by Xerox in 1979.
From 1972 to 1976, Jim was a general partner with Donaldson Lufkin & Jenrette's (DLJ) venture capital arm, the Sprout Capital Group. Prior to that, he served as a securities analyst with DLJ.
Trained as an aerospace engineer at MIT, Jim served as an Army officer and a missile systems engineer with the U.S. Army Missile Intelligence Directorate, serves on the Board of Overseers of the Hoover Institution at Stanford University and is a member of the Harvard School of Public Health's Health Policy and Management Executive Council. Jim was a director of the Western Association of Venture Capital.
Since 1979, David has been actively involved in managing and investing in over 60 high growth venture capital backed companies, primarily in the medical device industry. He joined Delphi Ventures in 1990. Prior to joining Delphi, David was a General Partner at Matrix Partners.
From 1984 to 1986, David served as Chief Operating Officer at Paladin Software Corporation responsible for operations, R&D, finance and administration. In 1979, David joined venture capital backed medical device company, Collagen Corporation. He was part of the Company’s original management team as Vice President of Finance and Administration and Chief Financial Officer. He was responsible for several private equity financings, corporate partnerships, as well as Collagen’s initial public offering. Before joining Collagen, David was a consultant with McKinsey & Company and a Teaching Fellow at Athens College in Greece.
David has been a member of the National Venture Capital Association Board of Directors and a trustee of the Stanford University DAPER Fund. He has served as a director of the Stanford University Athletic Board and as a member of the Stanford University School of Education Advisory Board. Additionally, David has been an adjunct professor at the University of Hawaii teaching New Venture Management and has served as Chairman of the Medical Industry Group of the National Venture Capital Association. Previously, he served as a director of the Western Association of Venture Capital. David has been named to the Forbes Midas List recognizing the top 100 venture capital investors. He is the inventor on 2 US issued medical device patents.
He earned his BA cum laude in political science from Amherst College and received an MBA and MA in Education from Stanford University.
